Good evening :)
Place Order
Add to Watchlist

Ami Organics Ltd

AMIORG

Ami Organics Ltd

AMIORG
Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,205 cr, stock is ranked 504
High RiskStock is 3.50x as volatile as Nifty
2,493.151.26% (-31.70)
2,493.151.26% (-31.70)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,205 cr, stock is ranked 504
High RiskStock is 3.50x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,205 cr, stock is ranked 504
High RiskStock is 3.50x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
84.0914.950.11%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.096.500.52%

Forecast & Ratings

Detailed Forecast 
80%
Analysts have suggested that investors can buy this stock

from 5 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

AMI Organics is a manufacturer of pharmaceutical preparation.

Investor Presentation

View older 

Jan 28, 2025

PDF
View Older Presentations
PE Ratio
43.84
1Y Return
16.69%
Buy Reco %
85.29
PE Ratio
28.85
1Y Return
2.17%
Buy Reco %
72.73
PE Ratio
66.58
1Y Return
23.00%
Buy Reco %
70.37
PE Ratio
54.32
1Y Return
18.22%
Buy Reco %
80.00
PE Ratio
18.53
1Y Return
0.43%
Buy Reco %
40.63
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 24.86%, vs industry avg of 9.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.11% to 0.19%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 12.91%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue156.57160.47191.18238.89242.48341.99522.90621.05724.96935.84
Raw Materialssubtract93.5894.75114.72151.95137.96174.87282.33345.85440.17733.40
Power & Fuel Costsubtract1.261.001.274.144.545.2621.4022.2825.82
Employee Costsubtract7.027.389.898.5412.9521.0141.3748.8463.11
Selling & Administrative Expensessubtract22.6017.6012.5614.7715.3812.1327.3436.6933.12
Operating & Other expensessubtract11.0516.4019.2617.0327.7947.1842.5140.4658.85
Depreciation/Amortizationsubtract0.801.371.912.603.524.1910.0812.3416.0624.23
Interest & Other Itemssubtract2.563.303.234.755.595.626.412.415.947.69
Taxes & Other Itemssubtract5.056.639.8611.817.2917.7219.5028.8839.1449.15
EPS4.023.825.877.408.7217.1521.1822.8611.6632.91
DPS0.000.000.000.000.000.003.003.003.003.00
Payout ratio0.000.000.000.000.000.000.140.130.260.09

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 16PDF
Feb 8PDF
FY 2023

Annual report

PDF

Investor Presentation

May 14PDF
Feb 4PDF
Nov 5PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2025

Annual Report Pending

Investor Presentation

Jan 28PDF
Oct 29PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Ami Organics Ltd238.7314.950.11%
Sun Pharmaceutical Industries Ltd43.846.260.77%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd66.5816.090.86%

Price Comparison

Compare AMIORG with any stock or ETF
Compare AMIORG with any stock or ETF
AMIORG
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.13%

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.65%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding35.96%13.68%6.56%15.52%28.28%

May 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

Dec '23MarMayJunSepDec '2411.65%8.97%10.01%12.92%13.87%15.52%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Ami Organics Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.7165%0.97%0.12%64/85 (+3)
1.8342%1.90%0.31%42/67 (+1)
1.2271%3.56%0.30%10/33 (+2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateJul 29, 2022

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Jul 29, 2022

News & Opinions
Spotlight
Ami Organics edge higher after PAT soars 155% YoY to Rs 45 crore in Q3 FY25

Revenue from operations jumped 65.21% to Rs 274.98 crore in Q3 FY25 as compared with Rs 166.44 crore in Q3 FY24. Total expenses grew by 45.87% YoY to Rs 213.32 crore during the quarter. Employee benefit expenses was at Rs 21.66 crore (up 34.28% YoY). The cost of material consumed stood at Rs 157.21 crore (up 82.52% YoY). Profit before tax stood at Rs 633.34 crore in Q3 FY25, marking a growth of 167.19% as against Rs 237.03 crore posted in Q3 FY24. EBITDA stood at Rs 68.70 crore in Q3 FY25, recording the growth of 159.24% as compared with Rs 26.50 crore in Q3 FY24. EBITDA margin improved by 25% during the quarter as compared with 15.9% posted in the corresponding quarter last year. Naresh Patel, executive chairman & MD, Ami Organics, said: I am delighted to share that in the first nine months of FY25, we achieved revenue of X698 crore, nearly equalling the revenue from operations of the entire previous financial year. In Q3FY25 alone, we delivered an impressive 65.2% year-on-year growth, achieving X275 crore in revenue from operations. This performance was driven by a strong ramp-up in our CDMO business and consistent growth in advanced pharmaceutical intermediates. Our pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, solidifying the foundation for sustained long-term growth. Ongoing discussions with innovators and partners remain highly encouraging, and we are confident that the CDMO segment will see exponential growth in the coming years. With improved visibility for Q4, I am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embracing adaptability, and seizing new opportunities that ensure sustainable and impactful growth.' Ami Organics is engaged in the business of drugs, intermediate chemicals, and related activities. Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Ami Organics consolidated net profit rises 168.36% in the December 2024 quarter

Net profit of Ami Organics rose 168.36% to Rs 44.95 crore in the quarter ended December 2024 as against Rs 16.75 crore during the previous quarter ended December 2023. Sales rose 65.22% to Rs 274.99 crore in the quarter ended December 2024 as against Rs 166.44 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales274.99166.44 65 OPM %24.9715.93 - PBDT69.6527.46 154 PBT63.3323.70 167 NP44.9516.75 168 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
AMI Organics to announce Quarterly Result

AMI Organics will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Ami Organics reports consolidated net profit of Rs 37.33 crore in the September 2024 quarter

Net profit of Ami Organics reported to Rs 37.33 crore in the quarter ended September 2024 as against net loss of Rs 18.85 crore during the previous quarter ended September 2023. Sales rose 43.15% to Rs 246.73 crore in the quarter ended September 2024 as against Rs 172.36 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales246.73172.36 43 OPM %19.8314.39 - PBDT56.8725.50 123 PBT50.0421.81 129 NP37.33-18.85 LP Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Ami Organics allots 6,950 equity shares under ESOS

Ami Organics has allotted 6,950 equity shares under ESOS on 14 October 2024. Pursuant to this allotment, the paid up share capital of the Company stands increased from Rs. 40,92,75,110/- (consisting of 4,09,27,511 equity shares of face value of Rs. 10/-each) to Rs. 40,93,44,610/- (consisting of 4,09,34,461 equity shares of face value of Rs. 10/- each). Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
AMI Organics to conduct AGM

AMI Organics announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
AMI Organics AGM scheduled

AMI Organics announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Ami Organics allots 21,950 equity shares under ESOS

Ami Organics has allotted 21,950 equity shares under ESOS. Pursuant to the allotment, the paid up equity share capital has increased to Rs. 40,92,75,110/- (consisting of 4,09,27,511 equity shares of face value of Rs. 10/- each). Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Ami Organics consolidated net profit declines 29.26% in the June 2024 quarter

Net profit of Ami Organics declined 29.26% to Rs 13.95 crore in the quarter ended June 2024 as against Rs 19.72 crore during the previous quarter ended June 2023. Sales rose 14.93% to Rs 176.67 crore in the quarter ended June 2024 as against Rs 153.72 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales176.67153.72 15 OPM %16.7122.12 - PBDT26.1334.65 -25 PBT19.9530.94 -36 NP13.9519.72 -29 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
AMI Organics to declare Quarterly Result

AMI Organics will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live